# Arrowhead Shares Rise After Alzheimer’s Drug Trial Data

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/31807
Published: 2026-10-14T12:49:56.000Z
Updated: 2026-10-14T12:49:56.000Z
Section: Business

> Arrowhead Pharmaceuticals said early-stage data for ARO-MAPT led it to declare initial clinical validation of its TRiM delivery platform.

Arrowhead Pharmaceuticals shares gained more than 4% in premarket trading Wednesday, Oct. 14, after the company declared initial clinical validation of its TRiM delivery platform based on early-stage trial data for its experimental Alzheimer’s therapy, ARO-MAPT.

ARO-MAPT is an RNA interference therapy. Arrowhead’s validation statement reflects the company’s assessment of the trial data.